MUMBAI, India, June 22 -- Intellectual Property India has published a patent application (202641069635 A) filed by Varikalla Rajashakar; Shraddha Shukla; Jyothirmai Namathoti; Dr. Maninder Pal Singh; Dr. Abhinav Anand; Dr. Rishab Bhanot; Dr. Narinderjit Kaur; Krishana Kumar Sharma; Shivam Sharma; and Ratna Ramchandra Chavan on June 03, 2026, for Design, Synthesis, Structural Characterization And Multi-Target Pharmacological Evaluation Of Quinoline–piperazine Hybrid Derivatives For Simultaneous Inhibition Of Monoamine Oxidase-B And Modulation Of Dopamine D2 Receptors For Neurovascular Disorders.
Inventors include Varikalla Rajashakar; Shraddha Shukla; Jyothirmai Namathoti; Dr. Maninder Pal Singh; Dr. Abhinav Anand; Dr. Rishab Bhanot; Dr. Narinderjit Kaur; Krishana Kumar Sharma; Shivam Sharma; and Ratna Ramchandra Chavan.
The application for the patent was published on June 12, 2026, under issue no. 24/2026.
Abstract: ABSTRACT The present invention relates to novel quinoline–piperazine hybrid derivatives designed and synthesized as multifunctional therapeutic agents for neurovascular and neurodegenerative disorders. The compounds exhibit dual pharmacological activity through simultaneous inhibition of Monoamine Oxidase-B (MAO-B) and modulation of Dopamine D2 receptors. The synthesized derivatives were structurally characterized using FTIR, ^1H NMR, ^13C NMR, mass spectrometry, and chromatographic techniques. Pharmacological evaluation demonstrated potent MAO-B inhibitory activity, dopamine receptor affinity, antioxidant action, neuroprotective effects, and reduction of oxidative stress. In vivo studies in neurovascular injury models revealed significant improvement in cerebral protection and neuronal survival. The invention further provides pharmaceutical compositions comprising the synthesized compounds for treatment of Parkinson’s disease, vascular dementia, cerebral ischemia, and related neurovascular disorders.
Disclaimer: Curated by HT Syndication.
